Study of Bendamustine, Velcade and Dexamethasone in the Treatment of Elderly Patients With Multiple Myeloma (BVD)

December 3, 2020 updated by: Intergroupe Francophone du Myelome

A Phase II Study of Bendamustine, Velcade and Dexamethasone (BVD) in the Treatment of Elderly Patients (>= 65 Years) With Multiple Myeloma in 1st Relapse or Refractory to 1st Line Therapy

The present trial is designed as a phase II study that aims at estimating the efficacy of the combination of bendamustine, bortezomib and dexamethasone in relapsed/refractory multiple myeloma (MM). The response rate, i.e. the rate of the patients achieving a Complete Response or Partial Response at cycle 4, divided by the total intent to treat patient number is chosen as primary efficacy endpoint.

The estimation of the efficacy rate is to be based on an explorative pilot study, since immediate embarking on a large-scale comparative efficacy trial would not be acceptable from the point of view of resources. Moreover, this would induce ethical objections, as it does not seem to be justifiable to expose a large number of patients to an experimental approach without sufficient exploratory indications of an improved risk-benefit ratio.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

After relapse or after early progression on first-line treatment, the prognosis of multiple myeloma (MM) patients is unfavourable, and the search for new treatment regimens, including drugs with novel mechanisms of action is essential.

Bendamustine and bortezomib have shown high activity boch in first-line regimens and pre-treated patients. The novel mechanism of action of the proteasome inhibitor and the non-cross resistance of bendamustine to other alkylating agents established in the first-line treatment of multiple myeloma seem to recommend a combination of the two drugs for salvage therapy (second-line regimen). Finally, the promising response data in a series of relapsing MM patients treated with bendamustine, bortezomib and prednisone support this assumption, as well as the feasibility and tolerability of the combination.

In summary, there is some evidence for a favorable risk/benefit ratio for the combination of bendamustine, bortezomib and a corticoid drug, warranting the exploration in a larger, prospectively designed multicenter phase II study.

Study Type

Interventional

Enrollment (Actual)

75

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Amiens, France, 80054
        • CHRU Hopital Sud
      • Angers, France, 49033
        • CHRU, Hôpital du Bocage
      • Avignon, France, 84902
        • Centre Hospitalier H.Duffaut
      • Bayonne, France, 64109
        • Centre Hospitalier de La Côte Basque
      • Besançon, France, 25030
        • Hôpital Jean Minjoz / CHU BESANCON
      • Blois, France, 41016
        • Centre hospitalier
      • Bobigny, France, 93009
        • Hôpital Avicenne
      • Bordeaux, France, 33000
        • Polyclinique Bordeaux Nord Aquitaine
      • Brest, France, 29609
        • Hôpital A.Morvan
      • Caen, France, 14076
        • Centre F.Baclesse
      • Clermont Ferrand, France, 63003
        • Chu Clermont Ferrand
      • Corbeil-essonnes, France, 91106
        • Ch Sud Francilien
      • Dijon, France, 21034
        • CHU Dijon, Hôpital Le Bocage
      • Dunkerque, France, 59385
        • Centre Hospitalier Général
      • Grenoble, France, 38043
        • Hôpital A.Michallon
      • La Roche Sur Yon, France, 85925
        • CH Départemental
      • Le Coudray, France, 28629
        • Centre Hospitalier de Chartres
      • Le Mans, France, 72000
        • Centre Jean Bernard
      • Lille, France, 59038
        • CHRU Hôpital Claude Huriez
      • Marseille, France, 13273
        • Institut Paoli Calmette
      • Meaux, France, 77104
        • CH Meaux
      • Nantes, France, 44035
        • CHRU Hôtel Dieu
      • Nice, France, 06202
        • Hôpital de l'Archet 1
      • Paris, France, 75005
        • Intitut Curie
      • Paris, France, 75571
        • CHU Hôpital St-Antoine
      • Pierre Benite, France, 69495
        • Centre Hopsitalier Lyon Sud
      • Pontoise, France, 95300
        • Centre Hospitalier René Dubos
      • Pringy, France, 74374
        • Centre hospitalier de la région d'Annecy
      • Reims, France, 51032
        • CHU Reims Hôpital R.Debré
      • Rennes, France, 35056
        • CHRU - Hôpital Sud
      • Rouen, France, 76038
        • Centre Henri Becquerel
      • Saint-cloud, France, 92210
        • Centre Rene Huguenin
      • Toulouse, France, 31059
        • CHRU Hopital Purpan
      • Tours, France, 37044
        • CHRU Hôpital Bretonneau
      • Valence, France, 26953
        • Centre hospitalier
      • Vandœuvre-lès-Nancy, France, 54511
        • CHRU - Hôpitaux de Brabois
      • Vannes, France, 56017
        • CH P.Chubert

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

61 years and older (Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Symptomatic multiple myeloma (MM) patient at the time of diagnosis (but not necessarily at the time of relapse), according to International Myeloma Working Group criteria.
  • Patient having received conventional chemotherapy in 1st line treatment because of age 65 years or over, or younger than 65 years and ineligible to high-dose therapy plus stem cell transplantation.
  • Measurable disease (≥10g/L monoclonal gammapathy and/or ≥ 200 mg/24h proteinuria or involved serum free light chain ≥ 100mg/L with abnormal FLC ratio < 0.26 or > 1.65)
  • Patient in 1st relapse or refractory to 1st line therapy. Relapse is defined by M-component increase of ≥25% from baseline, in serum and/or urine (the absolute increase in serum must be ≥ 5 g/l - the absolute increase of BJ proteins in urine must be ≥200 mg/24 h). (It is recommended to treat only symptomatic or rapidly evolutive relapses)
  • Life expectancy of at least 3 months
  • ECOG performance status <= 2 at study entry
  • Laboratory test results within these ranges:
  • Absolute neutrophil count >= 1.5 x 109/L
  • Platelet count >= 100 x 109/L
  • Serum creatinine <= 250 umol/l
  • AST (SGOT) and ALT (SGPT) <= 3 x ULN
  • Disease free of prior malignancies for >= 5 years, with exception of curatively treated basal cell, squamous cell carcinoma of the skin, or carcinoma "in situ" of the cervix or breast
  • Able to adhere to the study visit schedule and other protocol requirements
  • Using effective contraceptive methods during and for 6 months after study treatment (for fertile men, women of childbearing potential).
  • Provision of informed consent.
  • A period of at least 15 days must be respected between the last treatment of myeloma and the beginning of the study.

Exclusion Criteria:

  • Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form.
  • Any comorbidity which places the subject at unacceptable risk if he/she were to participate in the study.
  • Patients treated with high-dose therapy plus stem cell transplantation in 1st line therapy
  • Any prior use of bortezomib (Velcade) or bendamustine (Ribomustin)
  • Concurrent use of other anti-cancer agents or treatments other than those stated in this treatment plan
  • Use of any other experimental drug or therapy within 28 days prior to the start of study treatment.
  • Known hypersensitivity to the study drugs
  • Positive HIV serology, positive hepatitis C serology, active infection hepatitis A, active infection hepatitis B.
  • Severe cardiovascular disorders within 12 months prior to the start of study treatment (e.g. myocardial infarct, ischemic episodes, arrhythmias)
  • Previous major surgery less than 30 days before start of treatment
  • Active infection,
  • Pregnant or lactating women.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: BVD
Bendamustine, Velcade and Dexamethasone
Drug: Bendamustine, Velcade and Dexamethasone
Bendamustine : 70 mg/m2 iv on D1 and 8, for each cycle Velcade : 1.3 mg/m2 iv on D1, 8, 15 and 22, for each cycle Dexamethasone : 20 mg/day po on D1, 8, 15 and 22, given prior to Bendamustine and Velcade
Other Names:
  • Dexamethasone
  • Robimustin : Bendamustine
  • Velcade : Bortezomib

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
To assess of the overall response rate (complete response (CR) + partial response (PR))
Time Frame: After four 28-day consecutives cycles
After four 28-day consecutives cycles

Secondary Outcome Measures

Outcome Measure
Time Frame
Time to best response
Time Frame: the time from treatment start to the first detection of the best response category, calculated for all patients, which are not primarily refractory
the time from treatment start to the first detection of the best response category, calculated for all patients, which are not primarily refractory
Progression-free survival
Time Frame: The time form the initial dose of chemotherapy to the time of disease progression or death, or to the date of last assessment without any such event (censored observation)
The time form the initial dose of chemotherapy to the time of disease progression or death, or to the date of last assessment without any such event (censored observation)
Time to progression
Time Frame: The time from baseline to the development of progressive disease
The time from baseline to the development of progressive disease
Overall survival
Time Frame: The time interval from initial dose to the date of death or last observation (censored)
The time interval from initial dose to the date of death or last observation (censored)
Rate of additional response
Time Frame: Following 2 consolidation cycles and following 6 maintenance cycles
Following 2 consolidation cycles and following 6 maintenance cycles
Toxicity/Adverse events
Time Frame: From the time a signed and dated informed consent form is obtained until 60 days following the lase dose of study medication or until the start of a new subsequent antimyeloma therapy
From the time a signed and dated informed consent form is obtained until 60 days following the lase dose of study medication or until the start of a new subsequent antimyeloma therapy

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Intergroupe Francophone du Myelome

Investigators

  • Principal Investigator: Philippe RODON, Doctor, Unité Hématologie Biologique Institut Curie PARIS
  • Principal Investigator: Cyrille HULIN, Doctor, Service Hématologie Hôpitaux de Brabois VANDOEUVRE LES NANCY
  • Study Director: Jean-Luc HAROUSSEAU, Professor, Service Hématologie CHU Nantes
  • Study Chair: Claire MATHIOT, Doctor, IFM Hématologie Biologique Institut Curie PARIS
  • Study Chair: Marie-Odile PETILLON, Doctor, IFM Hôpital Claude Huriez Lille

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 3, 2010

Primary Completion (Actual)

March 28, 2013

Study Completion (Actual)

March 28, 2013

Study Registration Dates

First Submitted

January 7, 2010

First Submitted That Met QC Criteria

January 8, 2010

First Posted (Estimate)

January 11, 2010

Study Record Updates

Last Update Posted (Actual)

December 7, 2020

Last Update Submitted That Met QC Criteria

December 3, 2020

Last Verified

March 1, 2012

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • IFM2009-01
  • Eudract 2009-012359-91 (Registry Identifier: AFSSAPS)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Multiple Myeloma

Clinical Trials on Bendamustine, Velcade and Dexamethasone

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in China

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe